Moderna Shares Jump 9.4% on Positive Phase 3 Melanoma Vaccine Data

Yahoo Finance··US·Read original
3▲1 ▼0Impact / 5
Summary · why it matters

Moderna shares climbed 9.4% in the afternoon session as positive Phase 3 INTerpath-001 trial results for its personalized cancer vaccine, intismeran autogene, given alongside Merck's Keytruda in high-risk melanoma patients continued to drive momentum. The advance extended earlier gains from the clinical study rather than reflecting new company disclosures, and the stock has also been bolstered by Wall Street upgrades from Argus and Bank of America. Regulatory sentiment improved further after the Food and Drug Administration approved Moderna's updated 2026-2027 COVID-19 vaccines. These developments follow a $2.6 billion convertible note offering completed in late August to provide dedicated funding for ongoing oncology development. Moderna is up 442% since the beginning of the year and, at $167.16 per share, is trading close to its 52-week high of $174.38 from August 2026.

Impact on assets 3

Biotech & Genomic Medicine▲ · 2 stocks
Moderna Inc
MRNA
▲ PositiveTechnologyCapitalRegulationrelevance

Positive Phase 3 INTerpath-001 results for its personalized cancer vaccine intismeran autogene drove the 9.4% jump.

Merck & Company Inc
MRK
± MixedTechnologyrelevance

Keytruda is the combination partner in the positive Phase 3 melanoma trial, but the news is Moderna's vaccine data, not a Merck-specific development.

Critical Materials & Supply Chain▲ · 1 stocks
© 2026 MarketIVNews